Clinical trialNCT05890352RecruitingPhase 2Interventional

Study Adding Drugs to Usual Treatment for Large B-Cell Lymphoma That Returned or Did Not Respond to Treatment

SponsorSWOG Cancer Research NetworkEnrollment227Grade 3b Follicular LymphomaHigh Grade B-Cell LymphomaHigh Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 RearrangementsRecurrent Diffuse Large B-Cell LymphomaRefractory Diffuse Large B-Cell LymphomaTransformed Non-Hodgkin Lymphoma

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This phase 2 trial studies the side effects and best dose of tazemetostat and zanubrutinib in combination with tafasitamab and lenalidomide, and to see how well these combinations work in treating patients with large B-cell lymphoma that returned or did not respond to earlier treatment. Tazemetostat is in a class of medications called EZH2 inhibitors. It helps to stop the spread of cancer cells. Zanubrutinib is in a class of medications called kinase inhibitors. It works by blocking the action of the abnormal protein that signals cancer cells to multiply. This helps stop the spread of cancer cells. tafasitamab is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread. Lenalidomide is in a class of medications called immunomodulatory agents. It works by helping the bone marrow to produce normal blood cells and by killing abnormal cells in the bone marrow. The addition of tazemetostat or zanubrutinib to tafasitamab and lenalidomide may be able to shrink the cancer or extend the time without cancer symptoms coming back.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Jennifer E Amengual
SWOG Cancer Research Network
Principal Investigator
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

104 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

Banner University Medical Center - Tucson
Tucson, Arizona, United States
Krishna Rekha Moturi
Recruiting
University of Arizona Cancer Center-North Campus
Tucson, Arizona, United States
Krishna Rekha Moturi
Recruiting
Tower Cancer Research Foundation
Beverly Hills, California, United States
Akil A. Merchant
Recruiting
City of Hope Comprehensive Cancer Center
Duarte, California, United States
Alexey V. Danilov
Recruiting
City of Hope Seacliff
Huntington Beach, California, United States
Alexey V. Danilov
Recruiting
City of Hope Antelope Valley
Lancaster, California, United States
Alexey V. Danilov
Recruiting
City of Hope at Long Beach Elm
Long Beach, California, United States
Alexey V. Danilov
Recruiting
Cedars Sinai Medical Center
Los Angeles, California, United States
Akil A. Merchant
Recruiting
City of Hope Newport Beach
Newport Beach, California, United States
Alexey V. Danilov
Recruiting
City of Hope South Pasadena
South Pasadena, California, United States
Alexey V. Danilov
Recruiting
City of Hope South Bay
Torrance, California, United States
Alexey V. Danilov
Recruiting
City of Hope Upland
Upland, California, United States
Alexey V. Danilov
Recruiting
Holy Cross Hospital
Fort Lauderdale, Florida, United States
Tareq Al baghdadi
Recruiting
Mount Sinai Medical Center
Miami Beach, Florida, United States
Suspended
University of Chicago Comprehensive Cancer Center
Chicago, Illinois, United States
Justin P. Kline
Recruiting
University of Illinois
Chicago, Illinois, United States
Paul G. Rubinstein
Recruiting
Carle at the Riverfront
Danville, Illinois, United States
Suparna Mantha
Recruiting
Carle Physician Group-Effingham
Effingham, Illinois, United States
Suparna Mantha
Recruiting
Carle Physician Group-Mattoon/charleston
Mattoon, Illinois, United States
Suparna Mantha
Recruiting
Uc Comprehensive Cancer Center at Silver Cross
New Lenox, Illinois, United States
Justin P. Kline
Recruiting
University of Chicago Medicine-Orland Park
Orland Park, Illinois, United States
Justin P. Kline
Recruiting
Memorial Hospital East
Shiloh, Illinois, United States
Nancy L. Bartlett
Recruiting
Carle Cancer Center
Urbana, Illinois, United States
Suparna Mantha
Recruiting
Northwest Cancer Center - Main Campus
Crown Point, Indiana, United States
Suparna Mantha
Recruiting
Northwest Oncology Llc
Dyer, Indiana, United States
Suparna Mantha
Recruiting
Northwest Cancer Center - Hobart
Hobart, Indiana, United States
Suparna Mantha
Recruiting
Saint Mary Medical Center
Hobart, Indiana, United States
Suparna Mantha
Recruiting
Saint Catherine Hospital
Indianapolis, Indiana, United States
Suparna Mantha
Recruiting
the Community Hospital
Munster, Indiana, United States
Suparna Mantha
Recruiting
Women'S Diagnostic Center - Munster
Munster, Indiana, United States
Suparna Mantha
Recruiting
Northwest Cancer Center - Valparaiso
Valparaiso, Indiana, United States
Suparna Mantha
Recruiting
Ui Health Care Mission Cancer and Blood - Ankeny Clinic
Ankeny, Iowa, United States
Suspended
Mercy Hospital
Cedar Rapids, Iowa, United States
Deborah W. Wilbur
Recruiting
Oncology Associates at Mercy Medical Center
Cedar Rapids, Iowa, United States
Deborah W. Wilbur
Recruiting
Ui Health Care Mission Cancer and Blood - West Des Moines Clinic
Clive, Iowa, United States
Suspended
Mercy Medical Center - Des Moines
Des Moines, Iowa, United States
Richard L. Deming
Recruiting
Ui Health Care Mission Cancer and Blood - Laurel Clinic
Des Moines, Iowa, United States
Suspended
Trinity Health Saint Joseph Mercy Hospital Ann Arbor
Ann Arbor, Michigan, United States
Tareq Al baghdadi
Recruiting
Trinity Health Iha Medical Group Hematology Oncology - Brighton
Brighton, Michigan, United States
Tareq Al baghdadi
Recruiting
Trinity Health Medical Center - Brighton
Brighton, Michigan, United States
Tareq Al baghdadi
Recruiting

64 more sites on the registry record.ClinicalTrials.gov ↗

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Lenalidomide →Tafasitamab →Tazemetostat →Zanubrutinib →

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 26 Sept 2023
Primary completion: 31 Dec 2026
Completion: 31 Jan 2029
Last update posted: 20 Oct 2025
Registered enrollment: 227
Registry id: NCT05890352

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.